Mbx biosciences announces ind submission of mbx 4291, its long-acting glp1/gip receptor co-agonist prodrug for the treatment of obesity

Glp-1/gip receptor co-agonist designed to be highly potent and for once-monthly administration based on mbx's novel pep™ platform technology phase 1 trial of mbx 4291 is expected to initiate in q3 2025 carmel, ind., june 16, 2025 (globe newswire) -- mbx biosciences, inc. (nasdaq: mbx), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced submission of an investigational new drug (ind) application to the u.s. food and drug administration (fda) for mbx 4291, a long-acting glucagon-like peptide-1 (glp-1)/ glucose-dependent insulinotropic polypeptide (gip) receptor co-agonist prodrug for the treatment of obesity.
MBX Ratings Summary
MBX Quant Ranking